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BACKGROUND: Alternative treatments are needed for elderly patients with acute myeloid leukaemia, as the disease prognosis is poor
and the current treatment is unsuitable for many patients.
METHODS: In this study, we investigated whether combining the nucleoside analogue sapacitabine with histone deacetylase (HDAC)
inhibitors could be an effective treatment. Synergy and mode-of-action analysis were studied in cultured cell lines and the efficacy of
the combination was confirmed in a xenograft model.
RESULTS: CNDAC (1-(2-C-cyano-2-deoxy-b-D-arabino-pentofuranosyl)-cytosine), the active component of sapacitabine, synergised
with vorinostat in cell lines derived from a range of tumour types. Synergy was not dependent on a specific sequence of drug
administration and was also observed when CNDAC was combined with an alternative HDAC inhibitor, valproate. Flow cytometry
and western blot analysis confirmed that the combination induced a significant increase in apoptosis. Mode-of-action analysis detected
changes in Bcl-xl, Mcl-1, Noxa, Bid and Bim, which are all regulators of the apoptotic process. The sapacitabine/vorinostat
combination demonstrated significant benefit compared with the single-agent treatments in an MV4-11 xenograft, in the absence of
any observed toxicity.
CONCLUSION: Sapacitabine and HDAC inhibitors are an effective drug combination that is worthy of clinical exploration.
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Acute myeloid leukaemia (AML) is the most common type of acute
leukaemia in adults, with B12000 cases diagnosed in the United
States each year (Stone et al, 2004). Approximately two-thirds of
these patients are older than 60 years; the prognosis for elderly
AML patients is particularly poor, with a median survival of B2
months and a 6% 2-year survival rate (Menzin et al, 2002).
Conventional treatment for AML usually involves induction
therapy comprising the combination of an anthracycline with
the nucleoside analogue cytarabine. However, this treatment is
very intensive and many elderly patients are considered unfit
for induction treatment; accordingly there is a clear need for
alternative treatments.
CNDAC (1-(2-C-cyano-2-deoxy-b-D-arabino-pentofuranosyl)-
cytosine) is a 20-deoxycytidine analogue that was designed
specifically to have a novel DNA-strand-breaking mechanism of
action (Matsuda et al, 1991). In contrast to other deoxycytidine
analogues that block cells in the S-phase of the cell cycle (for
example, gemcitabine and cytarabine), CNDAC induces an S-phase
delay, followed by an arrest in G2. This effect is a function of the
cyano group, which promotes the induction of single-strand (ss)
DNA breaks after it has been integrated into DNA (Matsuda et al,
1991). These ssDNA breaks are converted into double-strand (ds)
DNA breaks, which activate the dsDNA repair pathway and result
in arrest at G2 (Liu et al, 2005). Sapacitabine (CS-682) is a
palmitoyl derivative of CNDAC (Hanaoka et al, 1999). The fatty-
acid side chain on the N4 group of the cytosine moiety improves
oral bioavailability and reduces inactivation by deamination.
Sapacitabine has improved efficacy over both gemcitabine and
cytarabine in xenograft models (Tanaka et al, 1992; Hanaoka et al,
1999). Sapacitabine has completed phase I studies in solid tumours
(Delaunoit et al, 2006; Gilbert et al, 2006) and haematological
malignancies (Kantarjian et al, 2010) in which promising activity
was reported. Sapacitabine is currently in phase II clinical trials in
AML, myelodysplastic syndrome (MDS) and non-small-cell lung
cancer (NSCLC).
Histone deacetylase (HDAC) inhibitors are a diverse series of
compounds being developed as anti-cancer agents (Bolden et al,
2006). The HDAC inhibitors promote increased protein acetyla-
tion, particularly of histones. Increased acetylation has a dramatic
effect on the conformation of histones and thereby the extent of
DNA supercoiling; this results in changes in the cellular gene
expression profile, by modulating access of transcription factors to
their DNA-binding sites (Momparler, 2003; Duan et al, 2005). The
failure of normal differentiation in haematological malignancies is
often associated with poor transcription of genes involved in
regulating the mature phenotype (Batty et al, 2009), suggesting
that these diseases could be attractive targets for HDAC inhibitor
treatment.
Sapacitabine has demonstrated clinical activity in a phase I
study involving leukaemia patients (Kantarjian et al, 2010),
whereas the HDAC inhibitors vorinostat and valproate have also
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selicited clinical responses in AML patients in phase I studies
(Bug et al, 2005; Garcia-Manero et al, 2008). In the clinic, most
anti-cancer drugs are used as part of a combination therapy, to
enhance efficacy, reduce toxicity and decrease drug resistance.
Thus the pre-clinical evaluation of the combination of these two
clinically active agents would determine whether the combination
could be worth clinical exploration. As CNDAC (Liu et al, 2005)
and most HDAC inhibitors (Bolden et al, 2006) promote increased
apoptosis through very different mechanisms, it was hypo-
thesised that a combination of these agents might significantly
stimulate cell death. This hypothesis was evaluated by combining
CNDAC with HDAC inhibitors in AML cell lines and in cell lines
derived from other tumours. The cellular effects of this combina-
tion were investigated in the AML cell line, MV4-11. Finally,
analysis of the combination in an MV4-11 mouse xenograft
model demonstrated that combination treatment significantly
reduced tumour growth compared with the single-agent treat-
ments, confirming that the combination was an effective in vivo
therapeutic option.
MATERIALS AND METHODS
Cell lines and reagents
MV4-11, Hut78, H460 and H1299 cells were purchased from ATCC
(Mannassas, VA, USA); PL21 and HL60 cells were obtained from
ECACC (Porton Down, UK); and Granta-519 cells were acquired
from DSMZ (Braunschweig, Germany). Cell cultures were main-
tained as recommended by the suppliers. All reagents were
purchased from Sigma (Poole, UK) unless stated otherwise.
Drug combination analysis
The cell lines were seeded in 96-well plates at the following cell
densities: Granta-519, 25000 cells per well; MV4-11, PL21 and
Hut78, 8000 cells per well; HL60, 5000 cells per well; H460, 3000 cells
per well; and H1299, 2000 cells per well. Stock solutions of CNDAC
(Cyclacel Ltd., Dundee, UK) and vorinostat (Toronto Research
Chemicals, North York, Canada) were prepared in dimethylsulph-
oxide. Valproate was dissolved in 0.9% (wt/vol) saline.
Three treatment regimens were explored (CNDAC pre-treat-
ment, HDAC inhibitor pre-treatment and concomitant treatment).
In most cell lines, a 72-h concomitant treatment regime was
employed. This involved simultaneous treatment of cells with
CNDAC and either vorinostat or valproate, alongside suitable
controls of cells treated with the individual compounds alone. A
48-h concomitant treatment regime was used in the AML cell lines.
In the adherent cell lines (H460 and H1299), sequential
treatment regimes involved adding one drug to the cells 2h after
plating, and leaving for a 24-h period. Media was then aspirated
and replaced with fresh media containing the second drug, which
was left for a further 72h. The two individual treatment controls
for the sequential treatment regime involved substituting one of
the drug treatments with drug-free media. A similar sequential
protocol was employed in the suspension cell lines, except that
medium was not aspirated from the cells after the 24-h pre-
treatment. Therefore, the concentration of the pre-treatment drug
was reduced on addition of fresh medium containing the second
agent. In addition, a 48-h treatment time was used for the second
drug treatment in the AML cell lines.
After the drug treatments were completed, the number of
viable cells in each well was estimated by incubating in media
containing 10% alamar blue (Roche, Lewes, UK) and measuring
the absorbance at 488–595nm. Drug interactions were analysed
using the Calcusyn software (BioSoft, Cambridge, UK). A
combination index (CI) value of 1 indicated an additive drug
interaction, whereas a CI value 41 suggested antagonism and a
value o1 denoted synergism.
Western blot analysis
MV4-11 and HL60 cells were seeded in 10-cm plates at 9 10
5 cells
per plate, Hut78 cells at 1.4 10
6 cells per plate and H460 cells at
6 10
5 cells per plate. Cells were treated with various concentra-
tions of CNDAC, vorinostat or a combination of these agents.
After incubation, cells were harvested by centrifugation at
2000r.p.m. for 5min, washed once with ice-cold buffer A (50mM
HEPES (pH 7.0), containing 20mM NaCl, 1mM DTT, 10mM
sodium pyrophosphate, 10mM sodium fluoride, 1mM sodium
orthovanadate and protease inhibitors) and then resuspended in
150ml of buffer A. All samples were lysed by sonication. Lysates
(10mg protein per well) were resolved on 12% acrylamide bis–tris
gels (Invitrogen, Paisley, UK) and the proteins transferred to
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany).
Membranes were blocked for 1h at room temperature in
phosphate-buffered saline containing 0.02% (vol/vol) Tween 20
(PBST) and 5% (wt/vol) fat-free dried milk. Membranes were
probed with the following primary antibodies: Noxa (Calbiochem,
Nottingham, UK), Mcl-1 and Bcl-xl (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), survivin (Abcam, Cambridge, UK), histone
H2AX, phosphoserine 139 histone H2AX, acetyl histone H4, Bcl-2,
Bax and Bim (Millipore, Watford, UK), XIAP and Asp-214 cleaved
PARP (poly-ADP ribose polymerase; BD Pharmingen, Oxford,
UK), PUMA, Bid and cleaved caspase 3 (Cell Signalling, Hitchin,
UK) and p53 (Oncogene, Nottingham, UK). Primary antibody
incubations were carried out overnight at 41C in PBST containing
3% (wt/vol) dried milk, with the exception of PUMA, which was
incubated in PBST containing 2% (wt/vol) bovine serum albumin.
Membranes were washed three times in PBST, and then incubated
for 1h with the appropriate horseradish-peroxidase-conjugated
secondary antibody (Pierce, Cramlington, UK) diluted in the ratio
1:6000 in PBST containing 3% (wt/vol) dried milk. Membranes
were washed three times in PBST before antibody detection using
ECL reagent (Amersham Corp., Little Chalfont, UK) or Immobilon
HRP substrate (Millipore).
Flow cytometry assays
The cell cycle profile was analysed by propidium iodide staining of
ethanol-fixed cells as described previously (Fleming et al, 2008).
Cells were seeded and treated as for western blots.
The Bax/Bak activation assay was performed as described
previously (Willis et al, 2005). Antibodies used in this experiment
were: activated Bax (6A7, Santa Cruz Biotechnology), activated
Bak (Ab1; Calbiochem) and fluorescein isothiocyanate (FITC)-
conjugated mouse secondary antibody (Abcam).
In vivo studies
Female (nu/nu) mice were injected subcutaneously with 1 10
7
MV4-11 cells resuspended in 50% Matrigel (BD Biosciences) at
a single site on their flanks. Once tumour volumes were
126–256mm
3 (16 days post-implantation) animals were pair
matched by tumour size into treatment groups (minimum of six
mice per group) with a mean tumour size of B190mm
3. Tumour
measurements were calculated using the formula: volume
(mm
3)¼width
2 (mm) length (mm) 0.5. Sapacitabine (Cyclacel
Ltd.) was prepared in 2.5% dimethylacetate and 9.75% emulphor
(Alkamuls EL-620, Rhodia, Cranbury, NJ, USA), whereas vorino-
stat was prepared in 40% hydroxypropyl-b-cyclodextrin vehicle.
Sapacitabine was administered once a day orally (5 or 15mgkg
 1)
for 4 days, followed by a 3-day break before another 4 days of
treatment; dosing started on the same day as distribution to the
treatment groups. Vorinostat (33mgkg
 1) was administered by
intraperitoneal injection once a day for 12 consecutive days
starting on the day after the mice were randomised. The groups
treated with the combination were dosed in the same manner as
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sboth the single-agent groups. Mice were weighed daily for 5 days of
treatment and then at least twice a week to assess toxicity.
No treatment-related deaths were seen in this experiment. The
tumours were measured at least twice a week to determine tumour
volume. The percent tumour growth inhibition (TGI) was
determined using the formula: 1 (mean change in treated tumour
volume/mean change in control tumour volume) 100. Statistical
significance for the experiment was determined using a one-way
analysis of variance (ANOVA) test. Significance between different
treatment groups was determined using a two-sided unpaired
Student’s t-test. Xenografts were performed at the Piedmont
Research Centre. Studies were reviewed by an internal board to
confirm that procedures complied with the recommendations of
the Guide for Care and Use of Laboratory Animals.
RESULTS
In vitro drug combination analysis of CNDAC and HDAC
inhibitors
The aim of this series of experiments was to determine whether
combining CNDAC with HDAC inhibitors would produce a
synergistic drug interaction. Initial evaluation of the combination
was carried out in the AML cell lines MV4-11, HL60 and PL21.
Combining CNDAC with either vorinostat (Table 1A) or valproate
(Table 1B) generated CI values that represented predomi-
nantly either synergistic or additive drug interactions. Three treat-
ment regimens were explored (CNDAC pre-treatment, HDAC
inhibitor pre-treatment and concomitant treatment); CNDAC
treatment before vorinostat generated slightly stronger synergy
(lower CI values) than the other schedules tested. The CNDAC/
valproate combination generated similar results with all three
schedules tested.
These findings were expanded to include cell lines derived from
other tumour types, including H460 and H1299 (NSCLC), Hut78
(cutaneous T-cell lymphoma) and Granta-519 (non-Hodgkin’s
lymphoma). The CNDAC/vorinostat combination predominantly
generated synergy in Hut78, Granta-519 and H1299 cells, whereas
it produced a mostly additive drug interaction in H460 cells
(Table 1A). Similarly, combination of CNDAC and valproate
produced synergy in H1299 cells and weak synergy/additivity in
H460 cells (Table 1B).
Overall, this series of results demonstrated that combining
CNDAC with an HDAC inhibitor produced a synergistic increase
in cytotoxicity in cell lines derived from diverse tumour types.
Synergy was observed in cell types that contain either wild-type
p53 (MV4-11, H460 and Granta-519) or mutant p53 (HL60, H1299
and Hut78), suggesting that the p53 status was not a critical factor
for the combination. Moreover, combining CNDAC with either
vorinostat or valproate produced broadly similar CI values in these
cell lines, suggesting that the observed synergy was a class effect,
and that the selection of the HDAC inhibitor did not appear to be
particularly crucial.
The combination of CNDAC and vorinostat induced cell
death in MV4-11 cells
MV4-11 cells were used for more in-depth analysis of the
combination, as this well-established AML model can be used
both in vitro and in vivo. To evaluate the cellular effects of the
combination in more detail, MV4-11 cell cycle profiles were
analysed by flow cytometry following treatment with compounds
at concentrations equivalent to their IC50 value (Figure 1A). A
CNDAC pre-treatment regimen was explored because this was the
most synergistic combination in the original cytotoxicity experi-
ments (Table 1A). Under the conditions tested, both the CNDAC
(C) (24h C, 24h m (media); 24h C, 48h m) and vorinostat (V)
(24h m, 24h V; 24h m, 48h V) single-agent treatments caused a
small increase in the number of cells in the sub-G1 cell population
(cells with a DNA content lower than normal diploid cells), which
is indicative of dead cells. On the other hand, the combination of
CNDAC followed by vorinostat (24h C, 24h V; 24h C, 48h V)
resulted in a dramatic increase in the sub-G1 population indicating
a synergistic increase in cell death at both the 48- and 72-h time
points. The total treatment time of 72h resulted in a greater
number of dead cells (53%) than the 48-h total treatment time
(36%). To optimise the synergistic interaction between the two
Table 1 Summary of combination studies involving CNDAC and either vorinostat or valproate
CNDAC pre-treatment Vorinostat pre-treatment Concomitant
Cell line ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90
(A)
MV4-11 1.19 0.86 0.68 0.87 0.77 0.73 1.04 0.86 0.77
HL60 1.18 0.76 0.53 1.31 0.97 0.89 1.20 0.97 0.98
PL21 0.99 0.71 0.53 1.12 0.87 0.70 1.29 0.97 0.73
Hut78 0.66 0.56 0.48 0.64 0.47 0.36 0.99 0.70 0.51
Granta-519 0.82 0.51 0.37 0.86 0.88 1.06 0.72 0.73 0.76
H460 0.93 0.91 0.94 1.63 1.58 1.57 0.85 0.99 1.18
H1299 2.24 0.42 0.60 0.66 0.84 1.90 0.63 0.59 0.99
CNDAC pre-treatment Valproate pre-treatment Concomitant
Cell line ED50 ED75 ED90 ED50 ED75 ED90 ED50 ED75 ED90
(B)
MV4-11 1.34 0.86 0.61 1.06 0.79 0.64 0.69 0.64 0.64
HL60 1.93 1.27 0.91 1.43 1.08 0.98 1.16 0.83 0.77
PL21 1.05 0.85 0.79 1.26 0.96 0.81 1.68 1.16 0.89
H460 1.13 0.98 0.86 1.34 1.16 1.01 1.59 1.30 1.10
H1299 1.01 0.93 0.88 0.71 0.59 0.65 0.69 0.56 0.62
Abbreviations: CNDAC¼1-(2-C-cyano-2-deoxy-b-D-arabino-pentofuranosyl)-cytosine; ED¼effective dose. CNDAC was tested in combination with either vorinostat (A) or
valproate (B) in various cell lines, using the protocol described in Materials and Methods. Concomitant and sequential treatment schedules were tested, and the resulting
combination index (CI) values shown for ED50,E D 75 and ED90 (the points on the curve where cellular proliferation is inhibited by 50, 75 and 90%, respectively). Results are the
average of at least three independent experiments. The CI value definitions are as follows: 1.45–1.2 is moderately antagonistic, 1.2–1.1 is slightly antagonistic, 1.1–0.9 is additive,
0.9–0.85 is slightly synergistic, 0.85–0.7 is moderately synergistic and 0.7–0.3 is synergistic.
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sagents, different concentrations of drug (corresponding to 0.5 ,
1  and 2  IC50) were evaluated during a 72-h incubation
(Figure 1B). CNDAC and vorinostat single-agent treatments
induced a dose-dependent increase in the sub-G1 cell population.
Combination of CNDAC with vorinostat induced a significant
increase in the sub-G1 cell population, compared with the single-
agent treatments; this effect was also dose dependent. The
induction of cell death was clearly synergistic when the
compounds were used at either 0.5  or 1  IC50, but only
appeared additive when used at 2  IC50; the apparent lack of
synergy at 2  IC50 was presumably because of the fact that both
single-agent treatments induced such a significant proportion of
cell death on their own, making it difficult to evaluate synergy.
Finally, in this initial set of experiments, MV4-11 cells were treated
with the CNDAC/vorinostat combination using the three treatment
schedules evaluated in the cytotoxicity experiments to ascertain
whether the sequence of compound administration had a
significant influence on the amount of cell death. The results
(Figure 1C) demonstrated that a synergistic increase in the sub-G1
cell population was seen for all three combination treatment
schedules, but the CNDAC pre-treatment (42%) and the con-
comitant treatment (41%) induced a slightly higher proportion of
cell death than the vorinostat pre-treatment (34%). This data
correlated well with the CI values detected in the cytotoxicity
experiments (Table 1A). These results indicated that the sequence
of administration was not critical for the combination, and
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Figure 1 Flow cytometry analysis of the CNDAC/vorinostat combination in MV4-11 cells. MV4-11 cells were treated with dimethylsulphoxide control
(m), CNDAC (C), vorinostat (V) or combinations of these agents (CV), as indicated. (A) Cells were treated for the indicated time periods using a schedule
involving 24-h CNDAC pre-treatment followed by vorinostat (for either 24 or 48h). Compounds were used at 1  IC50. The cell cycle profile was
determined after the total treatment time periods of either 48 or 72h. (B) The cell cycle profile of MV4-11 cells was analysed after treatment with various
concentrations of compound, using a schedule involving 24-h CNDAC pre-treatment followed by 48-h vorinostat. (C) The cell cycle profile was determined
after cells had been treated with different treatment regimes: CNDAC pre-treatment, concomitant treatment and vorinostat pre-treatment. Compounds
were used at 1  IC50. Results are given as the average ± s.d. of three independent experiments, except in panel B, which is the average ± s.d. of duplicate
experiments. CNDAC IC50¼0.46mM; vorinostat IC50¼0.4mM.
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ssuggested that the synergy was not the result of one treatment
blocking the cells in a specific phase of the cell cycle where the
second treatment was more effective.
Mode-of-action analysis of the CNDAC/vorinostat
combinations in MV4-11 cells
Western blot analysis was used to study the molecular changes that
were induced by the CNDAC/vorinostat combination (Figure 2).
Cells were initially treated with either CNDAC (C) or media (m) for
24h before an equivalent volume of media being added, which
was either drug free (m) or contained vorinostat (V), and the
incubation continued for a further 8–24h. As expected, vorinostat
stimulated an increase in histone acetylation. Similarly, CNDAC
enhanced p53 levels in MV4-11 cells, a property that has been
established for cytarabine (Kobayashi et al, 1998) and gemcitabine
(Achanta et al, 2001). The combination stimulated a modest
increase in histone H2AX phosphorylation at serine 139, over that
seen by either single agent. Phospho-H2AX is a marker of dsDNA
damage, but as this effect was relatively minor, it suggested that
enhancement of DNA damage was not the main cause of the
synergistic increase in cell death. The combination induced a
synergistic time-dependent increase in cleaved PARP, detectable
B16h after adding vorinostat to CNDAC-treated cells (Figure 2).
A synergistic increase in the active cleaved form of caspase 3, an
executioner caspase, became evident at the same time as the
cleaved PARP. These two observations confirmed that the increase
in cells with a sub-G1 DNA content (Figure 1) was because of the
induction of apoptosis.
Apoptosis is regulated by the Bcl-2 family proteins and the
related BH3-only proteins. These proteins can be divided into two
groups, with either pro- or anti-apoptotic roles; modifying the
levels or activity of these proteins disrupts the cellular apoptotic
balance. Western blots confirmed that treatment with the CNDAC/
vorinostat combination reduced the levels of the anti-apoptotic
proteins Mcl-1 and Bcl-xl to a much greater degree than either
individual compound, but had no significant effect on Bcl-2
(Figure 2). Overall, the loss of Mcl-1 and Bcl-xl would push the
cells towards apoptosis. The BH3-only proteins are a family of
small pro-apoptotic proteins that connect various stress stimuli
with the Bcl-2 proteins (Shibue and Taniguchi, 2006). Western blot
analysis was used to study the effect of combination treatment on
Noxa and PUMA, as CNDAC upregulated p53 protein levels
(Figure 2) and these proteins are transcriptionally activated by p53
(Shibue and Taniguchi, 2006). CNDAC treatment induced both
Noxa and PUMAa, whereas the combination induced a slightly
greater transient increase in Noxa, but had little effect on the levels
of PUMAa (Figure 2). The BH3-only protein Bid has an important
role in apoptosis through a mechanism that involves its own
degradation (Shibue and Taniguchi, 2006). CNDAC treatment
caused a time-dependent decrease in the level of full-length Bid,
which was enhanced by the combination with vorinostat (Figure 2),
suggesting that the induction of cell death involved the Bid
pathway. Another BH3-only protein, Bim, has three isoforms:
extra-long (EL), long (L) and short (S). Bim-S is constitutively
active, whereas Bim-EL and -L are regulated by reversible
phosphorylation (Wang et al, 2004; Shibue and Taniguchi, 2006).
All three isoforms of Bim were present in MV4-11 cells, and Bim-E
and -EL appeared to be composed of multiple bands. Both
vorinostat and the combination treatment enhanced the levels of
Bim-EL, consistent with previous vorinostat studies (Fandy et al,
2005; Zhao et al, 2005). Combination treatment also increased the
electrophoretic mobility of Bim-EL (Figure 2). Such a mobility
shift is consistent with a change in a protein’s phosphorylation
state; several studies have reported that dephosphorylation of
Bim-EL increases its electrophoretic mobility and stimulates
apoptosis by allowing Bim-EL to directly bind to and activate
Bax (Harada et al, 2004; Wang et al, 2004). The observed changes
in the BH3-only proteins Noxa, Bid and Bim occurred before
the increase in cleaved PARP, suggesting that they contributed
towards the increased apoptosis. In contrast, the CNDAC/
vorinostat combination did not induce dephosphorylation of Bad
(data not shown), suggesting that the combination does not
activate the Bad pro-apoptotic pathway. The combination also
promoted a modest downregulation of the caspase inhibitor XIAP
(Figure 2), which would also contribute to enhanced apoptosis.
The pro-apoptotic Bcl-2 family proteins Bax and Bak are the key
drivers of apoptosis; when activated, these proteins permeabilize
the outer mitochondrial membrane and promote the release of
pro-apoptotic factors (for example, cytochrome c) that activate
caspases and initiate the apoptotic cascade. Western blot analysis
demonstrated that the combination did not increase the expression
m C Cm mV CV Cm mV CV Cm mV CV
cPARP
24 h 24+8 h 24+16 h 24+24 h
Mcl-1
XIAP
Survivin
Bcl-2
p53
Noxa
Puma-
cCaspase3
Bcl-xl
Ac. Histone
H2AX
pH2AX
Bim-L
Bid
Bim-EL
Bim-S
Puma-
m C Cm mV CV Cm mV CV Cm mV CV
24 h 24+8 h 24+16 h 24+24 h
Figure 2 Combination of CNDAC and vorinostat induces selective modulation of apoptotic proteins in MV4-11 cells. MV4-11 cells were treated with
dimethylsulphoxide (m), 1  IC50 CNDAC (C), 1  IC50 vorinostat (V), or 1  IC50 CNDAC and vorinostat (CV). The schedule involved 24-h CNDAC
pre-treatment followed by vorinostat. Cells were harvested at 0, 8, 16 or 24h after addition of vorinostat, as indicated. The resulting lysates (10mg) were
resolved on 12% acrylamide bis–tris gels, transferred to nitrocellulose membranes and probed with the antibodies shown. cPARP, cleaved PARP; cCaspase 3,
cleaved caspase 3. The lower band in the XIAP blot represents XIAP, whereas the upper band is an unknown protein. Results are representative of two
independent experiments.
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sof either of these proteins (data not shown); hence, a flow
cytometry-based assay was performed to investigate whether the
observed increase in apoptotic cells involved activation of Bax or
Bak. When either Bax or Bak become activated, they undergo a
conformational change, which reveals a neo-epitope that is
recognised by specific antibodies. The antibodies are labelled with
the FITC dye; hence, cells with increased FITC signal contain
activated Bax or Bak. The results indicated that combining CNDAC
and vorinostat promoted activation of both Bax and Bak in
MV4-11 cells (Figure 3), and that the combination was slightly
more effective at activating Bak than Bax. As activation of Bax or
Bak reflects a commitment towards apoptotic cell death, these data
provide further evidence that the combination stimulated apop-
tosis in MV4-11 cells.
The combination of CNDAC and vorinostat can induce
apoptosis in cell lines derived from different tumour types
As combining CNDAC with vorinostat produced a significant
increase in the amount of apoptosis in MV4-11 cells (Figure 1),
these studies were expanded to ascertain whether the observed
cytotoxic synergy detected in other cell lines (Table 1) also
involved the induction of apoptosis. HL60, Hut78 and H460 cells
were chosen for further study, as they are from diverse tumour
types and exhibited a range of CI values with the CNDAC/
vorinostat combination. Based on the cytotoxicity data (Table 1)
an appropriate treatment regimen was selected for each cell line.
Cell cycle analysis demonstrated that combining CNDAC with
vorinostat significantly increased the population of cells with a
sub-G1 DNA content in HL60 and Hut78 cells and induced a
modest sub-G1 increase in H460 cells (Figure 4A). A similar trend
was observed by analysing the levels of cleaved PARP; combination
treatment induced a significant increase in PARP cleavage in HL60
and Hut78 cells and a moderate increase in H460 cells, compared
with the single-agent treatments (Figure 4B). These results were in
general agreement with the combination analysis data and confirm
that this combination appeared to be effective in cell lines derived
from multiple tumour types.
In vivo evaluation of sapacitabine and vorinostat in
combination
To determine whether these in vitro results translated into the
in vivo setting, the combination was evaluated in an MV4-11
xenograft (Figure 5). The palmitoyl derivative CNDAC prodrug,
sapacitabine, was used in vivo to maximise oral bioavailability.
There were no treatment-related deaths during the experiment,
suggesting that there was no adverse toxicity associated with the
combination. In the control group, some mice were killed due to
tumour burden (41000mm
3) on day 14; hence, this was
considered the experimental end point for statistical analysis. On
day 14, the single-agent treatments appeared to have a reduced
mean tumour size compared with the vehicle control (875mm
3).
However, at the low doses evaluated in this experiment, the impact
on tumour growth was relatively minimal, with all three single-
agent treatment groups reaching the experimental end point by
day 17. Unlike the single-agent treatments, combination of
vorinostat with sapacitabine provided clear benefit throughout
the course of the experiment. On Day 14, the sapacitabine
(5mgkg
 1) þ vorinostat (33mgkg
 1) group had a mean tumour
volume of 245mm
3 and a TGI of 92%, whereas the sapacitabine
(15mgkg
 1) þ vorinostat (33mgkg
 1) group had a mean tumour
volume of 107mm
3 and a TGI of 112%. An unpaired Student’s
t-test demonstrated that both combination treatments were
significantly different to the appropriate controls, which resulted
in an overall highly significant one-way ANOVA test (Po0.00001).
These data demonstrate that there was a clear benefit of combining
sapacitabine with vorinostat in this AML tumour model and that
the combination was effective in vivo.
DISCUSSION
Conventional treatment for AML involves combination of an
anthracycline with the nucleoside analogue cytarabine. However,
the poor prognosis for AML patients in general, and elderly
patients in particular (Menzin et al, 2002), means that alternative
therapies are required. In this report, we investigated whether
combining the novel nucleoside analogue CNDAC with HDAC
inhibitors could be an effective treatment option. The resulting
data provide compelling evidence that combining CNDAC with
HDAC inhibitors produces an effective cytotoxic combination,
both in vitro and in vivo. Moreover synergy was observed by
combining CNDAC with either vorinostat or valproate, suggesting
that there is a class effect between CNDAC and HDAC inhibitors.
Two distinct mechanisms can contribute towards synergy:
inhibition of cell growth or induction of cell death. Evidence from
multiple approaches demonstrated that the CNDAC/vorinostat
combination stimulated a large increase in cell death, suggesting
that this was making a significant contribution to the observed
synergy. First, cell cycle analysis demonstrated that combination
treatment induced a synergistic increase in cells with a sub-G1
DNA content (Figures 1 and 4); combining these agents killed
approximately 50–70% of the MV4-11 cell population when
treated at 1  IC50 for 72h (Figure 1A and B). Second, the
combination stimulated the conformational changes associated
with activation of the pro-apoptotic proteins Bax and Bak
(Figure 3), and increased the level of cleaved caspase 3 and
cleaved PARP (Figure 2), providing clear evidence of an increase in
apoptosis. Third, the data demonstrated that CNDAC synergised
with HDAC inhibitors in diverse cell lines derived from both
haematological malignancies and solid tumours (Table 1, Figures 1
and 4). These data demonstrate that the combination is effective in
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Figure 3 The CNDAC/vorinostat combination activates Bax and Bak
in MV4-11 cells. MV4-11 cells were treated with dimethylsulphoxide (m),
1  IC50 CNDAC (C), vorinostat (V) or both compounds in a sequen-
tial manner (CV). Combination treatment involved 24-h CNDAC pre-
treatment followed by 16-h vorinostat treatment. One of the drug
treatments was replaced by a drug-free media treatment in the two single-
agent controls (m). Cells were then harvested and the resulting lysates used
to measure the levels of activated Bax or Bak. Some of the samples were
incubated with secondary antibody in the absence of primary antibody
(secondary Ab) to assess non-specific binding of the FITC secondary
antibody. Results are the average ± s.d. of two independent experiments.
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sa range of different tumour types and that the efficacy of the
combination does not depend on a precise genetic signature.
Previous studies have investigated whether combining HDAC
inhibitors with nucleoside analogues stimulated apoptosis. Valpro-
ate enhanced the percentage of annexin V-positive cells induced by
cytarabine treatment in cultured AML cells (Siitonen et al, 2005).
Similarly, combining vorinostat with gemcitabine stimulated
apoptosis in NSCLC (Rundall et al, 2005) and pancreatic cancer
(Arnold et al, 2007) cell lines. None of these earlier combination
studies delineated a molecular mechanism that could account for
the observed increase in apoptosis. A recent review proposed
several different mechanisms to explain synergy between HDAC
inhibitors and other chemotherapeutic agents (Frew et al, 2009).
The simplest hypothesis was that pre-treatment with an HDAC
inhibitor increased the accessibility of DNA-damaging agents to
their target by altering the chromatin structure, thus enhancing the
cytotoxic effects. This hypothesis alone could not account for
the synergy between CNDAC and vorinostat, as there was no
schedule dependency for the combination (Figure 1C). A second
hypothesis implied that HDAC inhibitors could synergise with
DNA-damaging agents, either by inducing DNA damage them-
selves or suppressing the DNA repair process. It has been
demonstrated that HDAC inhibitor treatment can induce rapid
acetylation of histone proteins and phosphorylation of histone
H2AX, followed by the appearance of cleaved PARP several hours
later (Gaymes et al, 2006). In the data reported here, the
combination of CNDAC with vorinostat only induced a modest
increase in H2AX phosphorylation (Figure 2), which became
evident at the same time as the cleaved PARP. These data suggest
that the increase in H2AX phosphorylation was an early marker of
cell death rather than an apoptotic stimulus, indicating that the
synergy was not a result of the HDAC inhibitor contributing to
effects on DNA damage/repair. A third potential mechanism
behind the synergy was that HDAC inhibitors could sensitise cells
to the apoptotic effect of cytotoxic drugs by combining to decrease
the cellular apoptotic threshold, through altered expression of key
apoptotic regulators (Frew et al, 2009). As discussed below, the
data presented herein are consistent with this hypothesis.
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treatment followed by 48-h vorinostat treatment. The resulting lysates (20mg) were resolved on 12% acrylamide bis–tris gels, transferred to nitrocellulose
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sBak and Bax are the key drivers of apoptosis. Active Bax and Bak
permeabilize the mitochondrial outer membrane, releasing pro-
apoptotic proteins such as cytochrome c and Smac/DIABLO into
the cytosol, where they initiate and promote caspase activation.
The Bak and Bax activity is regulated by a complex interplay
between the anti-apoptotic Bcl-2 family members and the pro-
apoptotic BH3-only proteins. Recent studies have revealed that the
Bcl-2 family proteins only bind certain BH3-only proteins (Shibue
and Taniguchi, 2006): Bcl-2 interacts with Bad, Bim or PUMA;
Bcl-xl binds Bad, Bid, Bim or PUMA; and Mcl-1 is regulated by
Bim, PUMA or Noxa. The combination of CNDAC and vorinostat
produced discernable changes in the levels of a number of the
proteins that regulate apoptosis, including decreases in the anti-
apoptotic proteins Mcl-1 and Bcl-xl, and increases in the levels or
activation state of the pro-apoptotic BH3-only proteins Noxa, Bid
and Bim-EL (Figure 2). Modest molecular changes in all of these
proteins were caused by CNDAC and/or vorinostat single-agent
treatments, which suggested that the observed synergy was
probably a result of the concerted action of the two agents on
the apoptotic proteins. These changes would significantly disrupt
the interplay between the apoptotic regulatory proteins causing the
resultant activation of Bak and Bax and the induction of apoptosis.
Recent combination studies have suggested that targeting
multiple arms of the apoptotic regulatory machinery is an effective
strategy for killing cells (Chen et al, 2007; Rosato et al, 2007). Drug
combinations that target Mcl-1 and Bcl-2/Bcl-xl may mimic the
actions of more physiological regulators of apoptosis (Dai and
Grant, 2007), and selective targeting of multiple apoptotic path-
ways may overcome functional redundancy and force cells into
apoptosis. The in vitro studies presented here are consistent with
this hypothesis; the CNDAC/vorinostat combination (Table 1 and
Figure 1) targets multiple arms of the apoptotic machinery,
producing changes in the levels of key proteins involved in
regulating apoptosis (Figures 2–4).
Based on the promising in vitro data, the studies were expanded
into an in vivo MV4-11 xenograft model. The doses of both agents
were significantly below the previously reported maximum
tolerated doses (Hanaoka et al, 1999; Butler et al, 2000) and, as
would be expected, showed minimal efficacy when used as single
agents (Figure 5). However, the combination resulted in signifi-
cantly improved efficacy, including regressions in a number of
tumours at the higher dose levels tested. Moreover, the relatively
low doses of drug used meant that there was no associated toxicity
or weight loss in either of the single-agent arms or the combination
groups. Maximum mean weight loss for a group was o4%.
Although there was tumour re-growth once the dosing ceased,
treatment could have been continued for additional cycles, as the
agents were so well tolerated. The results of the MV4-11 xenograft
confirmed that the promising in vitro synergy translated into the
in vivo setting.
Owing to the limitations of the available therapy, there is an
urgent need for new therapeutic options for AML patients,
particularly those aged X70. Currently, both sapacitabine and
vorinostat are being evaluated in clinical studies, and have
reported single-agent activity in phase I studies in AML and
MDS patients (Garcia-Manero et al, 2008; Kantarjian et al, 2010).
Sapacitabine is being explored because of the well-established
activity of cytosine analogues such as cytarabine in myeloid
diseases. The HDAC inhibitors may be a good option, because in
myeloid malignancies, failure of normal differentiation often
results from an inability to transcribe genes that encode proteins
that either mediate or define the mature phenotype (Batty et al,
2009). For optimal transcription of these genes, histones should be
in a maximally acetylated state; hence, HDAC inhibitors could
provide a good therapeutic strategy for treating AML and other
haematological malignancies. The data reported herein suggest
that exploring the combination of sapacitabine and vorinostat in
the clinic would be a valid option, especially if they could be used
at reduced doses while maintaining improved efficacy.
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